Top 10 Companies in the SNAC for Semaglutide Market (2026): Market Leaders Driving Global Diabetes & Obesity Treatment

MARKET INSIGHTS

Global SNAC for Semaglutide market size was valued at USD 13 million in 2024 and is projected to reach USD 21.8 million by 2032, growing at a CAGR of 7.9% during the forecast period.

SNAC (Salcaprozate Sodium) is a critical absorption enhancer used in oral formulations of semaglutide, including products like Rybelsus®.

This pharmaceutical excipient plays a pivotal role in overcoming bioavailability challenges by temporarily modifying gastric pH and increasing intestinal permeability, thereby enabling effective absorption of peptide-based drugs in the gastrointestinal tract. The technology represents a significant advancement in diabetes and obesity treatment options by providing non-injectable alternatives to traditional GLP-1 receptor agonists.

The market growth is driven by increasing adoption of oral semaglutide formulations and expanding applications in weight management therapies. North America currently dominates the market, accounting for over 45% of global revenue in 2024, while Asia‑Pacific is expected to witness the fastest growth. Key manufacturers including Novo Nordisk, Apothecon Pharmaceuticals, and Actylis Lab are investing in production capacity expansion to meet rising demand, particularly for high‑purity (99%) SNAC formulations which currently represent nearly 80% of the market by volume.

SNAC for Semaglutide Market – View in Detailed Research Report

---

🔟 1. Novo Nordisk A/S

Headquarters: Bagsværd, Denmark
Key Offering: Rybelsus® (oral semaglutide) powered by SNAC technology

Novo Nordisk has pioneered the use of SNAC to deliver a highly bioavailable oral GLP‑1 receptor agonist, setting the benchmark for efficacy and safety in type 2 diabetes and weight management. The company’s global distribution network and robust R&D pipeline ensure sustained market leadership.

Sustainability & Growth Initiatives:

• Expansion of manufacturing capacity in North America and Asia‑Pacific
• Investment in green chemistry for SNAC synthesis
• Commitment to net‑zero emissions by 2035 across the supply chain

---

9️⃣ 2. Apothecon Pharmaceuticals

Headquarters: Wilmington, United States
Key Offering: High‑purity (99%) SNAC API for generics and branded products

Apothecon is a leading supplier of SNAC, providing critical raw material to global manufacturers. Their focus on quality and scalability supports the growing demand for oral semaglutide formulations.

Sustainability & Growth Initiatives:

• Implementation of ISO 14001 environmental management system
• Strategic partnerships with contract manufacturers in Asia
• Continuous improvement of impurity control to <0.1%

---

8️⃣ 3. Actylis Lab

Headquarters: Houston, United States
Key Offering: 99% purity SNAC for oral peptide drugs

Actylis Lab specializes in advanced excipient manufacturing, ensuring consistent product quality for oral semaglutide and other peptide therapeutics.

Sustainability & Growth Initiatives:

• Investment in renewable energy for production facilities
• Collaboration with academic institutions for formulation research
• Expansion of API production capacity to meet projected demand

---

7️⃣ 4. Hainan Poly Pharm

Headquarters: Haikou, China
Key Offering: Competitive pricing SNAC for the Chinese market

Hainan Poly Pharm leverages government‑supported manufacturing initiatives to provide cost‑effective SNAC to domestic and international customers.

Sustainability & Growth Initiatives:

• Adoption of water‑recycling technologies in production
• Compliance with China GMP and ISO 9001
• Expansion of regional distribution networks across ASEAN

---

6️⃣ 5. Suzhou Tianma Pharmaceutical Group Tianji Biopharmaceutical

Headquarters: Suzhou, China
Key Offering: High‑purity SNAC for global API supply

With state‑of‑the‑art facilities, Tianma delivers SNAC to leading pharmaceutical companies, supporting the shift to oral peptide therapies.

Sustainability & Growth Initiatives:

• Green manufacturing practices to reduce carbon footprint
• Partnerships with international GMP certification bodies
• Investment in next‑generation SNAC formulations

---

5️⃣ 6. Apeloa Pharmaceutical

Headquarters: Guangzhou, China
Key Offering: SNAC API for emerging markets

Apeloa focuses on scalable production of SNAC to meet the growing demand for oral semaglutide in developing economies.

Sustainability & Growth Initiatives:

• Implementation of ISO 14001 environmental standards
• Collaboration with local universities for research
• Expansion of production capacity by 30% by 2026

---

4️⃣ 7. Jiangsu Southeast Nanomaterials

Headquarters: Nanjing, China
Key Offering: SNAC for specialty pharmaceutical applications

Jiangsu Southeast Nanomaterials supplies high‑quality SNAC to niche markets, driving innovation in peptide drug delivery.

Sustainability & Growth Initiatives:

• Investment in nanotechnology for excipient optimization
• Adoption of ISO 9001 quality management
• Expansion of export capabilities to Europe and North America

---

3️⃣ 8. Bristol‑Myers Squibb

Headquarters: New York, United States
Key Offering: Research & development of next‑generation SNAC formulations

BMS is exploring advanced absorption enhancers to broaden the therapeutic portfolio of oral peptide drugs.

Sustainability & Growth Initiatives:

• Investment in sustainable manufacturing practices
• Collaboration with global partners for clinical trials
• Commitment to reduce CO₂ emissions by 25% by 2030

---

2️⃣ 9. GlaxoSmithKline

Headquarters: London, United Kingdom
Key Offering: Strategic sourcing of SNAC for oral biologics

GSK leverages its global supply chain to secure high‑quality SNAC for oral semaglutide and other peptide therapeutics.

Sustainability & Growth Initiatives:

• Investment in renewable energy for production sites
• Partnerships with academic research institutions
• Focus on circular economy principles in manufacturing

---

1️⃣ 10. Merck KGaA

Headquarters: Darmstadt, Germany
Key Offering: High‑purity SNAC for global pharmaceutical use

Merck provides SNAC to support the development of oral semaglutide and other peptide drugs across multiple therapeutic areas.

Sustainability & Growth Initiatives:

• Commitment to carbon neutrality by 2040
• Investment in green chemistry for excipient synthesis
• Expansion of API production in Europe and Asia

---

Download FREE Sample Report: SNAC for Semaglutide Market – View in Detailed Research Report

Get Full Report: SNAC for Semaglutide Market – View in Detailed Research Report

---

🌍 Outlook: The Future of SNAC for Semaglutide Market

The SNAC for semaglutide market is poised for sustained growth as oral GLP‑1 receptor agonists gain traction worldwide. Key drivers include increasing prevalence of diabetes and obesity, patient preference for oral therapy, and technological advancements that enhance bioavailability. The market is expected to reach USD 21.8 million by 2032, reflecting a CAGR of 7.9% over the forecast period.

---

📈 Key Trends Shaping the Market:

• Rapid expansion of oral semaglutide prescriptions in North America and Asia‑Pacific
• Emergence of weight‑management indications for semaglutide, broadening the therapeutic portfolio
• Continuous improvement of SNAC formulations to achieve up to 30% greater bioavailability
• Growth of generic competition following patent expirations, driving cost reductions
• Strategic collaborations between excipient manufacturers and biopharmaceutical companies to accelerate product development

These dynamics position SNAC as a critical enabler for the next wave of oral peptide therapeutics, ensuring enhanced patient adherence and improved health outcomes across the globe.